In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains
Open Access
- 20 April 2023
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 12 (4) , 785
Abstract
Cefiderocol is a new siderophore cephalosporin that is effective against multidrug-resistant Gram-negative bacteria, including carbapenem-resistant strains. The aim of this study was to evaluate the activity of this new antimicrobial agent against a collection of pathogens using broth microdilution assays and to analyze the possible mechanism of cefiderocol resistance in two resistant Klebsiella pneumoniae isolates. One hundred and ten isolates were tested, comprising 67 Enterobacterales, two Acinetobacter baumannii, one Achromobacter xylosoxidans, 33 Pseudomonas aeruginosa and seven Stenotrophomonas maltophilia. Cefiderocol showed good in vitro activity, with an MIC < 2 μg/mL, and was able to inhibit 94% of the tested isolates. We observed a resistance rate of 6%. The resistant isolates consisted of six Klebsiella pneumoniae and one Escherichia coli, leading to a resistance rate of 10.4% among the Enterobacterales. Whole-genome sequencing analysis was performed on two cefiderocol-resistant Klebsiella pneumoniae isolates to investigate the possible mutations responsible for the observed resistance. Both strains belonged to ST383 and harbored different resistant and virulence genes. The analysis of genes involved in iron uptake and transport showed the presence of different mutations located in fhuA, fepA, iutA, cirA, sitC, apbC, fepG, fepC, fetB, yicI, yicJ, and yicL. Furthermore, for the first time, to the best of our knowledge, we described two Klebsiella pneumoniae isolates that synthesize a truncated fecA protein due to the transition from G to A, leading to a premature stop codon in the amino acid position 569, and a TonB protein carrying a 4-amino acid insertion (PKPK) after Lysine 103. In conclusion, our data show that cefiderocol is an effective drug against multidrug-resistant Gram-negative bacteria. However, the higher resistance rate observed in Enterobacterales underlines the need for active surveillance to limit the spread of these pathogens and to avoid the risks associated with the emergence of resistance to new drugs.Keywords
This publication has 47 references indexed in Scilit:
- Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenemsJournal of Microbiology, Immunology and Infection, 2017
- Distribution of ESBLs, AmpC β-lactamases and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal and urinary tract infections in the Asia-Pacific region during 2008–14: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART)Journal of Antimicrobial Chemotherapy, 2016
- Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection MethodsFrontiers in Microbiology, 2016
- New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistanceInternational Journal of Antimicrobial Agents, 2016
- In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant StrainsAntimicrobial Agents and Chemotherapy, 2016
- Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic optionsFrontiers in Microbiology, 2015
- kSNP3.0: SNP detection and phylogenetic analysis of genomes without genome alignment or reference genomeBioinformatics, 2015
- Carbapenemase-Producing Gram-Negative Bacteria: Current Epidemics, Antimicrobial Susceptibility and Treatment OptionsFuture Microbiology, 2015
- Trimmomatic: a flexible trimmer for Illumina sequence dataBioinformatics, 2014
- Can Levofloxacin Be a Useful Alternative to Trimethoprim-Sulfamethoxazole for Treating Stenotrophomonas maltophilia Bacteremia?Antimicrobial Agents and Chemotherapy, 2014